GMP‐grade microcarrier and automated closed industrial scale cell production platform for culture of MSCs
Journal of Tissue Engineering and Regenerative Medicine · 2022-10 · 16 (10) · 934-944
DOI: 10.1002/term.3341 ↗At a glance
Journal article in Journal of Tissue Engineering and Regenerative Medicine, published online on 2022-08-05. Written by Yuanyuan Zhang and 12 co-authors. Institution: Department of Biomedical Engineering, School of Medicine, Tsinghua-Peking Center for Life Sciences, Tsinghua University, Beijing, China. Major MEDLINE topics: Mesenchymal Stem Cells. Cited 33 times so far (Crossref); 18 references. Funded by: National Science Fund for Distinguished Young Scholars.
Abstract (original language)
Efficient and large-scale expansion of mesenchymal stem/stromal cells (MSCs) has always been a formidable challenge to researchers in cell-based therapies and regenerative medicine. To reconcile major drawbacks of 2D planar culturing system, we innovatively developed an automated closed industrial scale cell production (ACISCP) platform based on GMP-grade microcarrier for culture of umbilical cord-mesenchymal stem/stromal cells (UCMSCs), in accordance with the criteria of stem cell bank. ACISCP system is a fully closed system, which employs different models of vivaSPIN bioreactors (CytoNiche Biotech, China) for scale-up cell culture and vivaPREP (CytoNiche Biotech, China) for automated cell harvesting and cell dosage preparation. To realize industrial scale expansion of UCMSCs, a three-stage expansion was conducted with 1 L, 5 and 15 L vivaSPIN bioreactors. Using 3D TableTrix® and ACISCP system, we inoculated 1.5 × 107 of UCMSCs into 1 L vivaSPIN bioreactor and finally scaled to two 15 L bioreactor. A final yield of 2.09 × 1010 cells with an overall expansion factor of 1975 within 13 days. The cells were harvested, concentrated, washed and prepared automatically with vivaPREP. The entire process was realized with ACISCP platform and was totally enclosed. Critical quality attributes (CQA) assessments and release tests of MSCs, including sterility, safety, purity, viability, identity, stability and potency were performed accordingly. The quality of cells harvested from 3D culture on the ACISCP and conventional 2D planar culture counterpart has no significant difference. This study provides a bioprocess engineering platform, harnessing GMP-grade 3D TableTrix® microcarriers and ACISCP to achieve industrial-scale manufacturing of clinical-grade hMSCs.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Biomedical Engineering, School of Medicine, Tsinghua-Peking Center for Life Sciences, Tsinghua University, Beijing, China.
- Beijing CytoNiche Biotechnology Co. Ltd, Beijing, China.
- National Institutes for Food and Drug Control, Beijing, China.
- Beijing Baylx Biotechnology Co. Ltd, Beijing, China.
- Center for Clinic Stem Cell Research, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China.
Funding
- National Science Fund for Distinguished Young Scholars
Cite
APA
Zhang, Y., Na, T., Zhang, K., Yang, Y., Xu, H., Wei, L., Xu, L., Yan, X., Liu, W., Liu, G., Wang, B., Meng, S., & Du, Y. (2022). GMP‐grade microcarrier and automated closed industrial scale cell production platform for culture of MSCs. Journal of Tissue Engineering and Regenerative Medicine, 16(10), 934-944. https://doi.org/10.1002/term.3341
Vancouver
Zhang Y, Na T, Zhang K, Yang Y, Xu H, Wei L, et al. GMP‐grade microcarrier and automated closed industrial scale cell production platform for culture of MSCs. Journal of Tissue Engineering and Regenerative Medicine. 2022;16(10):934-944. doi:10.1002/term.3341
BibTeX
@article{Zhang2022,
author = {Zhang, Yuanyuan and Na, Tao and Zhang, Kehua and Yang, Yanping and Xu, Huanye and Wei, Lina and Xu, Liming and Yan, Xiaojun and Liu, Wei and Liu, Guangyang and Wang, Bin and Meng, Shufang and Du, Yanan},
title = {GMP‐grade microcarrier and automated closed industrial scale cell production platform for culture of MSCs},
journal = {Journal of Tissue Engineering and Regenerative Medicine},
year = {2022},
volume = {16},
number = {10},
pages = {934--944},
doi = {10.1002/term.3341}
}
EUVIMED